Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

Trump previously selected Robert Francis Kennedy Jr. to head up the Department of Health and Human Services—the NIH’s parent ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

The academic-led, industry-partnered collaboration Equitable Breakthroughs in Medicine Development (EQBMED) has released an ...

Philips is expanding its collaboration with Amazon Web Services, focused on providing a cloud-based imaging diagnostics ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

A federal court jury has sided with Guardant Health, which had claimed that rival cancer test developer Natera went too far ...

Medigene will slim its head count by 40% and pause plans to get its first asset into the clinic in order to channel cash to ...